Search research articles
Contact Us
Filters
Showing results (161-170 of 176) with videos related to
Page
of 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Scientific Reports
|
April 13, 2026
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer
Valentina Thomas, Gift Nyamundanda, Adrian Lärkeryd, et al.
Nature Communications
|
September 7, 2022
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Nature Communications
|
November 14, 2022
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Cancer Research
|
April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Nature Genetics
|
April 5, 2020
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Alex H Wagner, Brian Walsh, Georgia Mayfield, et al.
Nature Medicine
|
October 13, 2015
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang, et al.
EMBO Molecular Medicine
|
November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Elena Garralda, Charles Abbott, Alma Calahorro, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 176) with videos related to
Sort By:
Page
of 18
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Scientific Reports
|
April 13, 2026
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer
Valentina Thomas, Gift Nyamundanda, Adrian Lärkeryd, et al.
Nature Communications
|
September 7, 2022
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Nature Communications
|
November 14, 2022
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Cancer Research
|
April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Nature Genetics
|
April 5, 2020
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Alex H Wagner, Brian Walsh, Georgia Mayfield, et al.
Nature Medicine
|
October 13, 2015
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang, et al.
EMBO Molecular Medicine
|
November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Elena Garralda, Charles Abbott, Alma Calahorro, et al.
Page
of 18